Insider Selling: Xeris Biopharma (NASDAQ:XERS) Director Sells $91,450.00 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Marla Persky sold 15,500 shares of the stock in a transaction dated Wednesday, June 3rd. The shares were sold at an average price of $5.90, for a total value of $91,450.00. Following the transaction, the director owned 126,500 shares in the company, valued at $746,350. This trade represents a 10.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Xeris Biopharma Price Performance

Shares of Xeris Biopharma stock opened at $6.18 on Monday. The company has a current ratio of 2.12, a quick ratio of 1.50 and a debt-to-equity ratio of 17.00. The firm has a market capitalization of $1.07 billion, a PE ratio of 103.00 and a beta of 0.78. The business’s 50-day moving average price is $6.10 and its 200-day moving average price is $6.59. Xeris Biopharma Holdings, Inc. has a 12 month low of $4.30 and a 12 month high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.01 EPS for the quarter. The firm had revenue of $83.13 million for the quarter, compared to analyst estimates of $79.83 million. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%. Sell-side analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current fiscal year.

Hedge Funds Weigh In On Xeris Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of XERS. UBS Group AG grew its position in Xeris Biopharma by 682.4% during the 3rd quarter. UBS Group AG now owns 1,782,734 shares of the company’s stock worth $14,511,000 after acquiring an additional 1,554,869 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Xeris Biopharma by 13.8% in the 4th quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock worth $87,815,000 after buying an additional 1,358,760 shares during the period. Qube Research & Technologies Ltd lifted its holdings in Xeris Biopharma by 67.5% in the 2nd quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company’s stock worth $14,429,000 after buying an additional 1,245,188 shares during the period. Goldman Sachs Group Inc. lifted its holdings in Xeris Biopharma by 75.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after buying an additional 1,199,435 shares during the period. Finally, Granahan Investment Management LLC lifted its holdings in Xeris Biopharma by 249.4% in the 4th quarter. Granahan Investment Management LLC now owns 1,223,404 shares of the company’s stock worth $9,604,000 after buying an additional 873,236 shares during the period. 42.75% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

XERS has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Xeris Biopharma in a research report on Monday, March 2nd. Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Finally, Wall Street Zen upgraded Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $10.80.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.